• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Elafibranor (Iqirvo) unveiled: a groundbreaking FDA-approved therapy revolutionizing primary biliary cholangitis treatment.

作者信息

Ahmed Iqra Furqan, Rizwan Fatima, Mansoor Haleema, Fakhoury Marc, Shaik Muzzamil Hussain, Gandhi Fenil, Belletieri Christopher

机构信息

Department of Internal Medicine, Liaquat National Hospital and Medical College, Karachi, Pakistan.

Department of Internal Medicine, Jinnah Sindh Medical University, Karachi, Pakistan.

出版信息

Ann Med Surg (Lond). 2024 Oct 17;86(12):6910-6912. doi: 10.1097/MS9.0000000000002672. eCollection 2024 Dec.

DOI:10.1097/MS9.0000000000002672
PMID:39649939
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11623839/
Abstract
摘要

相似文献

1
Elafibranor (Iqirvo) unveiled: a groundbreaking FDA-approved therapy revolutionizing primary biliary cholangitis treatment.艾拉非布诺（Iqirvo）亮相：一种经美国食品药品监督管理局批准的开创性疗法，彻底改变原发性胆汁性胆管炎的治疗方式。
Ann Med Surg (Lond). 2024 Oct 17;86(12):6910-6912. doi: 10.1097/MS9.0000000000002672. eCollection 2024 Dec.
2
Latest FDA approved drug Elafibranor (Iqirvo): a novel prospect for treatment of primary biliary cholangitis.美国食品药品监督管理局（FDA）最新批准的药物艾拉非布（Iqirvo）：治疗原发性胆汁性胆管炎的新希望。
Ann Med Surg (Lond). 2025 Jan 9;87(1):30-32. doi: 10.1097/MS9.0000000000002868. eCollection 2025 Jan.
3
Elafibranor (Iqirvo) for primary biliary cholangitis.用于原发性胆汁性胆管炎的艾拉非布诺（Iqirvo）。
Med Lett Drugs Ther. 2024 Dec 23;66(1718):202-204. doi: 10.58347/tml.2024.1718b.
4
Elafibranor: First Approval.依洛尤单抗：美国批准上市
Drugs. 2024 Sep;84(9):1143-1148. doi: 10.1007/s40265-024-02075-8. Epub 2024 Aug 7.
5
Seladelpar (Livdelzi) for primary biliary cholangitis.塞拉德尔帕（Livdelzi）用于原发性胆汁性胆管炎。
Med Lett Drugs Ther. 2025 Jan 20;67(1720):13-15. doi: 10.58347/tml.2025.1720d.
6
Iqirvo for primary biliary cholangitis - efficacy, safety, and future directions.Iqirvo用于原发性胆汁性胆管炎——疗效、安全性及未来方向。
Ann Med Surg (Lond). 2025 Mar 20;87(5):2758-2762. doi: 10.1097/MS9.0000000000003183. eCollection 2025 May.
7
Elafibranor: a breakthrough therapy revolutionizing primary biliary cholangitis (PBC) treatment.依拉非布胺：一种彻底改变原发性胆汁性胆管炎（PBC）治疗的突破性疗法。
Ann Med Surg (Lond). 2025 Jan 31;87(2):454-456. doi: 10.1097/MS9.0000000000002794. eCollection 2025 Feb.
8
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.Elafibranor 治疗原发性胆汁性胆管炎的疗效和安全性。
N Engl J Med. 2024 Feb 29;390(9):795-805. doi: 10.1056/NEJMoa2306185. Epub 2023 Nov 13.
9
A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.一项在原发性胆汁性胆管炎患者中进行的随机安慰剂对照试验，这些患者对 UDCA 治疗反应不完全。
J Hepatol. 2021 Jun;74(6):1344-1354. doi: 10.1016/j.jhep.2021.01.013. Epub 2021 Jan 21.
10
Prospects of elafibranor in treating alcohol-associated liver diseases.艾拉非布诺治疗酒精性肝病的前景。
World J Gastroenterol. 2025 Jan 14;31(2):99549. doi: 10.3748/wjg.v31.i2.99549.

引用本文的文献

1
Evolving therapeutic landscape of primary biliary cholangitis: A review.原发性胆汁性胆管炎不断演变的治疗前景：综述
World J Hepatol. 2025 Jul 27;17(7):107223. doi: 10.4254/wjh.v17.i7.107223.
2
Obeticholic Acid Improves Cholestasis, Liver Fibrosis, and Liver Function in Patients with Primary Biliary Cholangitis with Inadequate Response to Ursodeoxycholic Acid.奥贝胆酸可改善对熊去氧胆酸反应欠佳的原发性胆汁性胆管炎患者的胆汁淤积、肝纤维化及肝功能。
J Pers Med. 2025 Feb 21;15(3):79. doi: 10.3390/jpm15030079.

本文引用的文献

1
Elafibranor emerged as a potential chemotherapeutic drug for non-muscle invasive bladder cancer.依拉非尼成为一种用于非肌层浸润性膀胱癌的潜在化疗药物。
Cell Insight. 2024 Jan 29;3(1):100149. doi: 10.1016/j.cellin.2024.100149. eCollection 2024 Feb.
2
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.Elafibranor 治疗原发性胆汁性胆管炎的疗效和安全性。
N Engl J Med. 2024 Feb 29;390(9):795-805. doi: 10.1056/NEJMoa2306185. Epub 2023 Nov 13.
3
Primary biliary cholangitis: Epidemiology, prognosis, and treatment.原发性胆汁性胆管炎：流行病学、预后和治疗。
Hepatol Commun. 2023 Jun 2;7(6). doi: 10.1097/HC9.0000000000000179. eCollection 2023 Jun 1.
4
Management of Primary Biliary Cholangitis: Current Treatment and Future Perspectives.原发性胆汁性胆管炎的管理：当前治疗与未来展望。
Turk J Gastroenterol. 2023 Feb;34(2):89-100. doi: 10.5152/tjg.2023.22239.
5
PPAR agonists for the treatment of primary biliary cholangitis: Old and new tales.用于治疗原发性胆汁性胆管炎的过氧化物酶体增殖物激活受体激动剂：新老故事
J Transl Autoimmun. 2023 Jan 5;6:100188. doi: 10.1016/j.jtauto.2023.100188. eCollection 2023.
6
Beneficial effects of elafibranor on NASH in E3L.CETP mice and differences between mice and men.依洛尤单抗对 E3L.CETP 小鼠 NASH 的有益作用及其与人类的差异。
Sci Rep. 2021 Mar 3;11(1):5050. doi: 10.1038/s41598-021-83974-8.
7
A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.一项在原发性胆汁性胆管炎患者中进行的随机安慰剂对照试验，这些患者对 UDCA 治疗反应不完全。
J Hepatol. 2021 Jun;74(6):1344-1354. doi: 10.1016/j.jhep.2021.01.013. Epub 2021 Jan 21.
8
Current understanding of primary biliary cholangitis.原发性胆汁性胆管炎的现有认识。
Clin Mol Hepatol. 2021 Jan;27(1):1-21. doi: 10.3350/cmh.2020.0028. Epub 2020 Dec 3.
9
Liver Injury in Patients With Cholestatic Liver Disease Treated With Obeticholic Acid.接受奥贝胆酸治疗的胆汁淤积性肝病患者的肝损伤
Hepatology. 2020 Apr;71(4):1511-1514. doi: 10.1002/hep.31017. Epub 2020 Mar 24.
10
The Pathogenesis of Primary Biliary Cholangitis: A Comprehensive Review.原发性胆汁性胆管炎的发病机制：全面综述。
Semin Liver Dis. 2020 Feb;40(1):34-48. doi: 10.1055/s-0039-1697617. Epub 2019 Sep 19.